Brazikumab

Unassigned

New Medicines

Moderate-severe Crohn's disease and ulcerative colitis

Information

New molecular entity
AstraZeneca
AstraZeneca

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Monoclonal antibody that binds to the IL23 receptor
The prevalence in the UK is about 145 per 100,000 population, increasing in incidence. Around 20% of children with Crohns will need biologic agents [3]. With current therapies 40% to 55% of patients have no response to therapy, this treatment offers an alternative [1].
Moderate-severe Crohn's disease and ulcerative colitis
Intravenous